Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARC: Elayta SV2A PET Study in Alzheimer's Disease
NCT03493282Phase 2Completed
- Sponsor
- Cognition Therapeutics, Inc.
- Start
- Mar 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pirfenidone in Alzheimer's disease (AD), sponsored by Cognition Therapeutics, Inc.. Started Mar 2018; status: completed.
02
Drugs
pirfenidone
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03493282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03493282.